Foley special counsel Mary Hendrickson is speaking in a Strafford webinar panel titled “Inflation Reduction Act’s Medicare Prescription Payment Plan: New CMS Guidance” on May 1. This CLE program will provide guidance to health care counsel on the Inflation Reduction Act’s (IRA) Medicare Prescription Payment Plan. The panel will examine the new Centers for Medicare & Medicaid Services (CMS) guidance as well as the operational changes and requirements necessary to implement the changes. The panelists will discuss the potential implications for reimbursement and offer best practices for implementing the changes.
This session will review these and other key considerations:
- What guidance has been provided as to how the payment plan works?
- What parameters does the guidance place on sponsors to effectuate new processes?
- What impact may the IRA Payment Plan have on reimbursement?
People
Related Insights
December 4, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
December 4, 2025
Foley Viewpoints
Foley Event Key Takeaways- Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shift
Foley & Lardner, Protiviti and SS&C Intralinks recently hosted an event in Foley’s Silicon Valley office at Palo Alto Center. Moderated by Foley partner Louis Lehot, the session titled "Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shifts," brought together industry leaders: JD Fay (ex-CFO, Matterport, de-SPAC’d and then sold to CoStar Group), Dan Angus (Managing Director, Nasdaq), and Andrea Vardaro Thomas (Managing Director, Protiviti). Their combined experience provided a roadmap for companies facing the volatile and rapidly shifting capital markets of 2026.
December 4, 2025
Foley Viewpoints
FDA Guidance on Biosimilars Highlights Glycosylation Profiling and Increases the Strategic Value of Patents Covering Antibodies Defined by Glycosylation
FDA’s September 2025 guidance requires detailed characterization of posttranslational modifications (PTMs), particularly glycosylation,…